ArticleThe Pan African medical journal2025
Revision of medicine prices and sales price evolution in Moroccan pharmacies.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Morocco adopted a new medicines pricing policy in 2013 that introduced price revisions following the implementation of Decree No. 2-13-852. This study aims to describe the evolution in medicine price decreases in Moroccan pharmacies following the price revisions published by the Ministry of Health. Methods: as part of a retrospective descriptive study, all the price revision lists over five years (2014-2019) were crossed with the databases of sales of medicines sold in pharmacies. Results: price decrease affected 1704 medicines, 54% of which were originator drugs. All therapeutic classes were involved, 22.7% were anti-infective, and 18.5% were for the cardiovascular system. Medicines with a public selling price between 5 and 10 US dollars (25.4%) were the most affected by the drop, even if it has concerned all price ranges. 22.8% of medicines decreased by less than or equal to 0.1 US dollar, and 28.7% recorded decreases of less than or equal to 1% of the public selling price. Five medicines (0.3%) have been reduced by over 70%, with 73.2% as a maximum drop percentage. Conclusion: following the implementation of Decree no. 2-13-852, a series of medicine price revisions was adopted. All price ranges and therapeutic classes were affected by the price decrease, with several variations. However, complementary policies are still needed to improve access to medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.